Skip to content

Treatment of Proximal Humeral Fractures

An International, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Conservative, Plate Fixation and Prosthesis in Treatment of Displaced 2, 3, and 4 Part Fractures of Proximal Humerus of 60 Years and Older Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01246167
Acronym
TPHF
Enrollment
250
Registered
2010-11-23
Start date
2011-01-31
Completion date
2019-11-30
Last updated
2020-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Humeral Fractures, Proximal

Keywords

Proximal humerus fracture, conservative, locking plate, Philos, Hemiprosthesis

Brief summary

This trial is designed to compare head-to-head conservative with operative treatment in 2 stratum. Stratum 1: In 2 part fractures the comparison is between conservative treatment and operative treatment with plate fixation with Philos. Stratum 2: In multi-fragmented fractures (MFF) meaning 3 and 4 part fractures, the comparison is between conservative treatment, operative treatment with Philos plate and operative treatment with Epoca prosthesis. Subgroup analysis will be performed in an effort to obtain limit values for specific treatment of different age and fracture groups. A cost-effectiveness analysis and comparison between different treatment modalities will be carried out. The primary outcome measure will be the DASH score and the secondary outcome measure the EQ-5D value. Recruitment period is 3 years and follow-up 2 years.

Interventions

DEVICEPhilos

Conservative treatment versus Philos locking plate in 2 part fracture group. Conservative treatment versus Philos locking plating versus Epoca prosthesis in MFF group.

DEVICEEpoca

Conservative treatment versus Philos locking plate versus Epoca fracture prosthesis in MFF group

OTHERControl group

Conservative control group

Sponsors

Kuopio University Hospital
CollaboratorOTHER
Jyväskylä Central Hospital
CollaboratorOTHER
Karolinska University Hospital
CollaboratorOTHER
Tampere University
CollaboratorOTHER
Academy of Finland
CollaboratorOTHER
Uppsala University Hospital
CollaboratorOTHER
Aarhus University Hospital
CollaboratorOTHER
Regionaalhaigla, Tallinn
CollaboratorUNKNOWN
Tartu University Hospital
CollaboratorOTHER
Tampere University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Low energy proximal humeral displaced (more than 1 cm or 45 degrees) 2 part fracture where fracture line emerges through the surgical (or anatomical) neck * Low energy proximal humeral displaced (more than 1 cm or 45 degrees) 3 or 4 part fracture

Exclusion criteria

* Refuse to participate the study * Less than 60 years old * Non-independent * Dementia and/or institutionalized * Does no understand written and spoken guidance in either Finnish or Swedish * Pathological fracture or previous fracture in the same proximal humerus * Serious intoxicant dependent, eg. In first aid breathalyzer shows more than 2‰ * Other operational injury in the same upper limb * Major nerve injury (eg. Complete radialis- or delta palsy) * Open fracture * Multi-trauma or -fractured patient * Fracture dislocation or head splitting fracture * Undisplaced fracture * Isolated tuberculum fracture * Fracture has no precondition to ossify by conservative treatment (no bony contact between fracture parts or the humeral shaft is in contact with the articular surface) * Treating surgeon considers patient unsuitable to attend the study on medical basis * Cuff-arthropathy

Design outcomes

Primary

MeasureTime frameDescription
DASH6 monthsto measure physical function and symptoms of the fractured shoulder

Secondary

MeasureTime frameDescription
EQ-5D6 monthIndividual's general health related quality of life is measured with EQ-5D

Countries

Denmark, Estonia, Finland, Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026